share_log
Breakings ·  Aug 29 20:30
Orgenesis Inc: Top-Line Efficacy and Safety Data From Study Had a Complete Response (Cr )of 82% in Adult Patients and 93% in Pediatric Patients
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment